Do analysts recommend OXB or SCLP?

Oxford Biomedica currently has a consensus price target of GBX 604.32, suggesting a potential upside of 5.65%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, research analysts plainly believe Oxford Biomedica is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, SCLP or ERGO?

Ergomed has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scancell £4.71M 50.36 -£6.75M -£0.55 N/A Ergomed £152.09M 0.00 £15M £0.29 N/A

Is SCLP or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Ergomed's return on equity. Company Net Margins Return on Equity Return on Assets Scancell -116.98% 90.29% -45.28% Ergomed 9.87% 18.08% 10.16%

Do analysts prefer AVCT or SCLP?

Avacta Group presently has a consensus target price of GBX 99, indicating a potential upside of 41.43%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Avacta Group is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, AVCT or SCLP?

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 2,809.33 -£30.08M -£17.55 N/A Scancell £4.71M 50.36 -£6.75M -£0.55 N/A

Is AVCT or SCLP more profitable?

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% Scancell -116.98% 90.29% -45.28%

Do analysts rate PRTC or SCLP?

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 309.02%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRTC or SCLP more profitable?

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health -2,355.32% -31.98% -13.39% Scancell -116.98% 90.29% -45.28%

Scancell (SCLP) Competitors

GBX 22.86 -0.89 (-3.75%)

As of 12:36 PM Eastern

Compare

SCLP vs. OXB, ERGO, SLN, AVCT, and PRTC

Should you buy Scancell stock or one of its competitors? MarketBeat compares Scancell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scancell include Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), Avacta Group (AVCT), and PureTech Health (PRTC). These companies are all part of the "biotechnology" industry.

How does Scancell compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Oxford Biomedica has a net margin of -17.85% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Scancell	-116.98%	90.29%	-45.28%

Scancell has lower revenue, but higher earnings than Oxford Biomedica. Scancell is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.10	-£143.51M	-£26.92	N/A
Scancell	£4.71M	50.36	-£6.75M	-£0.55	N/A

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 25.9% of Oxford Biomedica shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oxford Biomedica has a beta of 1.095, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Scancell has a beta of 0.573, suggesting that its stock price is 43% less volatile than the broader market.

Oxford Biomedica currently has a consensus price target of GBX 604.32, suggesting a potential upside of 5.65%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, research analysts plainly believe Oxford Biomedica is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica had 3 more articles in the media than Scancell. MarketBeat recorded 3 mentions for Oxford Biomedica and 0 mentions for Scancell. Oxford Biomedica's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Scancell	Neutral

Summary

Oxford Biomedica beats Scancell on 11 of the 15 factors compared between the two stocks.

How does Scancell compare to Ergomed?

Scancell (LON:SCLP) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

In the previous week, Scancell's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Ergomed	Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 15.5% of Scancell shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ergomed has a net margin of 9.87% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Ergomed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Ergomed	9.87%	18.08%	10.16%

Scancell has a beta of 0.573, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Ergomed has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	50.36	-£6.75M	-£0.55	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

Summary

Ergomed beats Scancell on 9 of the 10 factors compared between the two stocks.

How does Scancell compare to Silence Therapeutics?

Scancell (LON:SCLP) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Scancell's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scancell	Neutral
Silence Therapeutics	Neutral

Silence Therapeutics has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Silence Therapeutics	N/A	N/A	N/A

1.5% of Scancell shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	50.36	-£6.75M	-£0.55	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

Summary

Scancell and Silence Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Scancell compare to Avacta Group?

Avacta Group (LON:AVCT) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Scancell has a beta of 0.573, meaning that its stock price is 43% less volatile than the broader market.

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,809.33	-£30.08M	-£17.55	N/A
Scancell	£4.71M	50.36	-£6.75M	-£0.55	N/A

2.6% of Avacta Group shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 50.9% of Avacta Group shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Scancell	-116.98%	90.29%	-45.28%

Avacta Group presently has a consensus target price of GBX 99, indicating a potential upside of 41.43%. Given Avacta Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Avacta Group is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Scancell. Avacta Group's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
Avacta Group	Neutral
Scancell	Neutral

Summary

Avacta Group beats Scancell on 10 of the 15 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

PureTech Health (LON:PRTC) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

34.6% of PureTech Health shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 13.4% of PureTech Health shares are held by company insiders. Comparatively, 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Scancell has higher revenue and earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	64.89	-£91.86M	-£46.00	N/A
Scancell	£4.71M	50.36	-£6.75M	-£0.55	N/A

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Scancell	-116.98%	90.29%	-45.28%

PureTech Health has a beta of 0.788, indicating that its share price is 21% less volatile than the broader market. Comparatively, Scancell has a beta of 0.573, indicating that its share price is 43% less volatile than the broader market.

In the previous week, PureTech Health's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Scancell	Neutral

PureTech Health currently has a consensus target price of GBX 508, indicating a potential upside of 309.02%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PureTech Health beats Scancell on 8 of the 14 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLP vs. The Competition

Export

Metric	Scancell	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£237.24M	£464.32M	£6.47B	£2.78B
Dividend Yield	N/A	3.87%	2.69%	6.13%
P/E Ratio	-41.56	3.11	18.89	364.74
Price / Sales	50.36	6,509.16	520.79	87,565.33
Price / Cash	7.86	13.13	41.34	27.85
Price / Book	-58.65	84.75	9.84	7.71
Net Income	-£6.75M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-7.45%	-0.06%	-1.16%	0.07%
1 Month Performance	51.39%	0.75%	3.85%	3.26%
1 Year Performance	128.60%	74.31%	27.40%	75.52%

Scancell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLP Scancell	N/A	GBX 22.86 -3.7%	N/A	+137.5%	£237.24M	£4.71M	N/A	51
OXB Oxford Biomedica	0.996 of 5 stars	GBX 634.75 +1.2%	GBX 687 +8.2%	+75.0%	£767.54M	£168.74M	N/A	891	News Coverage Analyst Forecast Gap Down
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.6465 of 5 stars	GBX 76.45 +1.3%	GBX 99 +29.5%	+102.7%	£346.72M	£113K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SCLP) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scancell (SCLP) Competitors

SCLP vs. OXB, ERGO, SLN, AVCT, and PRTC

How does Scancell compare to Oxford Biomedica?

Summary

How does Scancell compare to Ergomed?

Summary

How does Scancell compare to Silence Therapeutics?

Summary

How does Scancell compare to Avacta Group?

Summary

How does Scancell compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scancell (SCLP) Competitors

SCLP vs. OXB, ERGO, SLN, AVCT, and PRTC

How does Scancell compare to Oxford Biomedica?

Is OXB or SCLP more profitable?

Which has preferable valuation & earnings, OXB or SCLP?

Do institutionals & insiders have more ownership in OXB or SCLP?

Which has more risk and volatility, OXB or SCLP?

Do analysts recommend OXB or SCLP?

Does the media favor OXB or SCLP?

Summary

How does Scancell compare to Ergomed?

Does the media favor SCLP or ERGO?

Do institutionals & insiders hold more shares of SCLP or ERGO?

Is SCLP or ERGO more profitable?

Which has more volatility & risk, SCLP or ERGO?

Which has higher valuation and earnings, SCLP or ERGO?

Summary

How does Scancell compare to Silence Therapeutics?

Does the media favor SCLP or SLN?

Is SCLP or SLN more profitable?

Do institutionals & insiders have more ownership in SCLP or SLN?

Which has higher earnings & valuation, SCLP or SLN?

Summary

How does Scancell compare to Avacta Group?

Which has more volatility and risk, AVCT or SCLP?

Which has preferable valuation and earnings, AVCT or SCLP?

Do institutionals and insiders believe in AVCT or SCLP?

Is AVCT or SCLP more profitable?

Do analysts prefer AVCT or SCLP?

Does the media refer more to AVCT or SCLP?

Summary

How does Scancell compare to PureTech Health?

Do institutionals & insiders hold more shares of PRTC or SCLP?

Which has preferable earnings and valuation, PRTC or SCLP?

Is PRTC or SCLP more profitable?

Which has more volatility and risk, PRTC or SCLP?

Does the media favor PRTC or SCLP?

Do analysts rate PRTC or SCLP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools